Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: A systematic review of risk prediction models

Journal of Clinical Oncology

Volumn 32, Issue 3, 2014, Pages 238-250

  Engelhardt, Ellen G ^a   Garvelink, Mirjam M ^a   De Haes, J C J M ^b   Van Der Hoeven, Jacobus J M ^a   Smets, Ellen M A ^b   Pieterse, Arwen H ^a   Stiggelbout, Anne M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; FEMALE; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; INTERPERSONAL COMMUNICATION; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TUMOR RECURRENCE; UNCERTAINTY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEALTH POLICY; HEALTH SERVICES MISUSE; HUMANS; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TRUTH DISCLOSURE; UNCERTAINTY;

EID: 84897019508     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.3417     Document Type: Review

References (81)

1. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5-23, 2011
2. Mook S, Knauer M, Bueno-de-Mesquita JM, et al: Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 17:1406-1413, 2010
3. de Snoo F, Bender R, Glas A, et al: Gene expression profiling: Decoding breast cancer. Surg Oncol 18:366-378, 2009
4. Bernards R, Weinberg RA: A progression puzzle. Nature 418:823, 2002 (Pubitemid 34966286)
5. Schmidt M, Victor A, Bratzel D, et al.: Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer: Comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 20:258-264, 2009
6. Goldhirsch A, Wood WC, Gelber RD, et al: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144, 2007 (Pubitemid 47244357)
7. Haybittle JL, Blamey RW, Elston CW, et al: A prognostic index in primary breast cancer. Br J Cancer 45:361-366, 1982 (Pubitemid 12122304)
8. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001 (Pubitemid 32176272)
9. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
10. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002 (Pubitemid 34130608)
11. Love N: Management of breast cancer in the adjuvant and metastatic settings: Patterns of care in medical oncology. http://www.patternsofcare.com/ 2005/3/adjuvant.htm
12. Agarwal V, O'Neill P: Adjuvant! Online as a decision-making tool in early breast cancer: A UK national survey. Clin Oncol (R Coll Radiol) 23:159-160, 2011
13. Liu Y, Pérez M, Aft RL, et al: Accuracy of perceived risk of recurrence among patients with early-stage breast cancer. Cancer Epidemiol Biomarkers Prev 19:675-680, 2010
14. Belkora JK, Hutton DW, Moore DH, et al: Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication? J Natl Compr Canc Netw 9:707-712, 2011
15. Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. Genet Med 11:3-14, 2009
16. Aebi S, Davidson T, Gruber G, et al: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22:vi12-vi24, 2011 (suppl 6)
17. National Comprehensive Cancer Network (NCCN): NCCN Guidelines: Breast Cancer version 1.2012. http://www.nccn.org
18. National Institute for Health and Clinical Excellence (NICE): Diagnostics consultation document: Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management - MammaPrint, Oncotype DX, IHC4 and Mammostrat. Provisional recommendations. http://guidance.nice.org.uk/DT/4/Consultation/DraftGuidance/ pdf/English
19. National Institute for health and Clinical Excellence (NICE): Early and locally advanced breast cancer: Diagnosis and treatment. http://www.nice.org.uk/ cg80
20. Gnant M, Harbeck N, Thomssen C: St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 6:136-141, 2011
21. Schwartz GF, Reis-Fihlo J, Pusztai L, et al: Adjuvant therapy in stage I carcinoma of the breast: The influence of multigene analyses and molecular phenotyping. Cancer 118:2031-2038, 2012
22. Simpson D: Readability test tool. http://www.read-able.com/
23. Campbell HE, Gray AM, Harris AL, et al: Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer 103:776-786, 2010
24. Wishart GC, Bajdik CD, Azzato EM, et al: A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol 37:411-417, 2011
25. Michaelson JS, Chen LL, Bush D, et al: Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat 128:827-835, 2011
26. Kattan MW, Giri D, Panageas KS, et al: A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer 101:2509-2515, 2004 (Pubitemid 39532279)
27. Aubele M, Auer G, Voss A, et al: Disease-free survival of node-positive breast cancer patients: Improved prognostication by cytometrical parameters. Pathol Res Pract 191:982-990, 1995
28. Chang H, Sneddon J, Alizadeh A, et al: Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2:E7, 2004
29. Haibe-Kains B, Desmedt C, Rothe F, et al: A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biol 11:R18, 2010
30. Ma XJ, Salunga R, Dahiya S, et al: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14:2601-2608, 2008
31. Ma Y, Qian Y, Wei L, et al: Population-based molecular prognosis of breast cancer by transcriptional profiling. Clin Cancer Res 13:2014-2022, 2007 (Pubitemid 46649867)
32. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
33. Pawitan Y, Bjöhle J, Amler L, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. Breast Cancer Res 7:R953-R964, 2005
34. Ring BZ, Seitz RS, Beck R, et al: Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 24:3039-3047, 2006 (Pubitemid 46638938)
35. Sigurdsson H, Baldetorp B, Borg A, et al: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322:1045-1053, 1990 (Pubitemid 20146663)
36. Van Laar RK: Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival. J Mol Diagn 13:297-304, 2011
37. Wang Y, Klijn JG, Zhang Y, et al: Geneexpression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005 (Pubitemid 40260888)
38. Xu L, Tan A, Winslow R, et al: Merging microarray data from separate breast cancer studies provides a robust prognostic test. Bmc Bioinformatics 9:125, 2008
39. Wishart GC, Bajdik CD, Dicks E, et al: PREDICT Plus: Development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 107:800-807, 2012
40. Albergaria A, Ricardo S, Milanezi F, et al: Nottingham Prognostic Index in triple-negative breast cancer: A reliable prognostic tool? BMC Cancer 11:299, 2011
41. Balslev I, Axelsson CK, Zedeler K, et al: The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 32:281-290, 1994 (Pubitemid 24351375)
42. D'Ereditá G, Giardina C, Martellotta M, et al: Prognostic factors in breast cancer: The predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37:591-596, 2001
43. Sidoni A, Bellezza G, Cavaliere A, et al: Prognostic indexes in breast cancer: Comparison of the Nottingham and Adelaide indexes. Breast 13:23-27, 2004 (Pubitemid 38228584)
44. Blamey RW, Ellis IO, Pinder SE, et al: Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 43:1548-1555, 2007 (Pubitemid 46901016)
45. Galea MH, Blamey RW, Elston CE, et al: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207-219, 1992
46. Kollias J, Murphy CA, Elston CW, et al: The prognosis of small primary breast cancers. Eur J Cancer 35:908-912, 1999 (Pubitemid 29277123)
47. Todd JH, Dowle C, Williams MR, et al: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489-492, 1987 (Pubitemid 17146357)
48. Bhoo-Pathy N, Yip CH, Hartman M, et al: Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer 48:982-989, 2012
49. Campbell HE, Taylor MA, Harris AL, et al: An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 101:1074-1084, 2009
50. Hajage D, de RY, Bollet M, et al: External validation of Adjuvant! Online breast cancer prognosis tool: Prioritising recommendations for improvement. PLoS One 6:e27446, 2011
51. Paridaens RJ, Gelber S, Cole BF, et al: Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 123:303-310, 2010
52. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005 (Pubitemid 46179461)
53. Mook S, Schmidt MK, Rutgers EJ, et al: Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: A hospital-based retrospective cohort study. Lancet Oncol 10:1070-1076, 2009
54. Wittner BS, Sgroi DC, Ryan PD, et al: Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 14:2988-2993, 2008
55. Buyse M, Loi S, van't Veer L, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192, 2006 (Pubitemid 44390989)
56. Ishitobi M, Goranova TE, Komoike Y, et al: Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol 40:508-512, 2010
57. Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al: Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 117:483-495, 2009
58. Mook S, Schmidt MK, Weigelt B, et al: The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21:717-722, 2010
59. Mook S, Schmidt MK, Viale G, et al: The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116:295-302, 2009
60. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
61. Yorozuya K, Takeuchi T, Yoshida M, et al: Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer. J Cancer Res Clin Oncol 136:939-944, 2010
62. Habel L, Shak S, Jacobs M, et al: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25, 2006
63. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
64. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
65. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
66. Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, et al: Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann Oncol 22:2021-2030, 2011
67. Gevensleben H, Göhring UJ, Büttner R, et al: Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer. Int J Mol Med 26:837-843, 2010
68. Hartmann S, Gerber B, Elling D, et al: The 70-gene signature as prognostic factor for elderly women with hormone receptor-positive, HER2-negative breast cancer. Breast Care 7:19-24, 2012
69. Na KY, Kim KS, Lee JE, et al: The 70-gene prognostic signature for Korean breast cancer patients. J Breast Cancer 14:33-38, 2011
70. Smyth GK, Speed T: Normalization of cDNA microarray data. Methods 31:265-273, 2003 (Pubitemid 37338763)
71. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
72. Tang G, Cuzick J, Costantino JP, et al: Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29:4365-4372, 2011
73. Pusztai L: Anatomy and biology: Two complementary sides of breast cancer prognostication. J Clin Oncol 29:4347-4348, 2011
74. DREAM Project: Sage Bionetworks-DREAM Breast Cancer Prognosis Challenge. http://www.the-dream-project.org/challenges/sage-bionetworks-dream-breast- cancer-prognosis-challenge
75. Hornberger J, Alvarado MD, Rebecca C, et al: Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: A systematic review. J Natl Cancer Inst 104:1068-1079, 2012
76. Zikmund-Fisher BJ, Fagerlin A, Ubel PA: Improving understanding of adjuvant therapy options by using simpler risk graphics. Cancer 113:3382-3390, 2008
77. Senay I, Kaphingst KA: Anchoring-andadjustment bias in communication of disease risk. Med Decis Making 29:193-201, 2009
78. Lagarde SM, Franssen SJ, van Werven JR, et al: Patient preferences for the disclosure of prognosis after esophagectomy for cancer with curative intent. Ann Surg Oncol 15:3289-3298, 2008
79. Zeguers M, de Haes HC, Zandbelt LC, et al: The information needs of new radiotherapy patients: How to measure? Do they want to know everything? And if not, why? Int J Radiat Oncol Biol Phys 82:418-424, 2012
80. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, et al: Helping doctors and patients make sense of health statistics. Psychol Sci Publ Interest 8:53-96, 2007
81. Lipkus IM: Numeric, verbal, and visual formats of conveying health risks: Suggested best practices and future recommendations. Med Decis Making 27:696-713, 2007